PatentOct 5, 2026, 07:01 AM
Satellos Bioscience Granted Key Patent for Forazapadin
AI Summary
Satellos Bioscience Inc. announced the issuance of a U.S. composition of matter patent for its lead drug candidate, forazapadin. This patent, valid through September 6, 2044, protects forazapadin and related AAK1 inhibitors, strengthening the company's intellectual property estate. Forazapadin is currently in Phase 2 development for Duchenne muscular dystrophy (DMD) and is expected to enter Phase 2 trials for facioscapulohumeral muscular dystrophy (FSHD) in late 2026. The company views this patent as a significant advancement for its long-term development and commercialization strategy.
Key Highlights
- Satellos Bioscience Inc. has been granted a composition of matter patent (U.S. Patent No. 12,747,245) for forazapadin.
- The patent provides U.S. intellectual property protection through September 6, 2044.
- Forazapadin is Satellos' lead clinical-stage drug candidate for degenerative muscle diseases.
- The patent covers forazapadin and a broader class of AAK1 inhibitors.
- Satellos is advancing forazapadin in Phase 2 clinical studies for Duchenne muscular dystrophy (DMD) and expects to begin a Phase 2 study for facioscapulohumeral muscular dystrophy (FSHD) in Q4 2026.
Price Impact
More from MSLE